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Conclusions: In patients with recurrent GBM, CTV-Gd and 
CTV-T2 differed considerably from CTV-MPET. At least 5 mm 
margin to CTV-T2 would be necessary in the target volume 
delineation of recurrent GBM to cover CTV-MPET in the re-
irradiation planning. 
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Purpose/Objective: The aim of this study is to evaluate the 
reliability of MRI fusion for the determination of target 
volume when performing CT based intracranial stereotactic 
radiosurgery.  
Materials and Methods: Patients treated with CT based 
intracranial stereotactic radiosurgery with various diagnoses 
are included in the study. All patients were immobilized 
using stereotactic thermoplastic masks prior to simulation. 
The planning CT was obtained both with and without iv 
contrast with 1mm slice thickness. The images obtained were 
then fused with 3D, T1 weighted MR images with contrast by 
two different platforms (Eclipse 10.0, Velocity 3.0 rigid and 
Velocity 3.0 deformable). The target volume was contoured 
by the same physician in four different image sets (planning 
CT with iv contrast, planning CT fused with MRI by Eclipse 
software, planning CT fused with MRI with Velocity rigid 
fusion algorithm software, planning CT fused with MRI with 
Velocity deformable fusion algorithm software). The target 
volumes delineated on planning CT with iv contrast were 
determined as reference volume. The intersections of all 
volumes delineated with three different fusion algorithms 
were produced and ratios of the intersections were 
calculated. Values close to one was determined as the unit of 
similarity and were compared with Paired-Samples t test. The 
center of each target was determined and offsets were 
calculated according to the reference.  
Results: Eight intracranial targets were evaluated. All of the 
targets evaluated were clearly visualized in the planning CT 
with iv contast. Six of these lesions were metastases while 
the remaining two were meningioma. The median volume of 
the delineated targets on the planning CT with iv contrast 
was 9.53 cc. The intersecting volume with three different 
fusion algorithms (Eclipse fusion, Velocity rigid fusion and 
Velocity deformeable fusion) was 8.08, 6.74 and 6.84 cc 
respectively. The ratios of the intersections were 1.20, 1.42 
and 1.40 where all of these differences were significant 
(p=0.004, p=0.010 ve p=0.009). The maxiumum offset in each 
fusion was in Y axis and the most in velocity deformable 
fusion (mean 0.3 cm; 0.02-0.76cm). There was difference 
between offsets for the lesion which are close to or away 
from the bone. 
Conclusions: Determining the target volume with MRI fusion 
when performing CT based intracranial stereotactic 
radiosurgery may not be very reliable compared to obtaining 
a planning CT with iv contrast. Careful attention must be 
paid to this as this might affect not only the treatment 
outcomes but also the late toxicity.  
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Purpose/Objective: To analyse the survival after salvage 
radiosurgery and to identify the prognostic factors 
Materials and Methods: We retrospectively reviewed 87 
consecutive patients, with recurrent high-grade glioma, that 
underwent stereotactic radiosurgery between 1997 and 2010. 
We evaluated the survival after initial diagnosis and after re-
irradiation. The prognostic factors were analysed by bivariate 
and multivariate Cox regression model. 
Results: The median age was 48 years old. The primary 
histology included anaplastic astrocytoma (47%) and 
glioblastoma (53%). A margin dose of 18Gy was administered 
in the majority of cases (74%). The median survival after 
initial diagnosis was 21 months (39 months for anaplastic 
astrocytoma and 18.5 months for glioblastoma) and after re-
irradiation was 10 months (17 months for anaplastic 
astrocytoma and 7.5 months for glioblastoma). In the 
bivariate analyses the prognostic factors significantly 
associated with the survival after re-irradiation were: age, 
tumour and treatment volume at recurrence, recursive 
partitioning analyses classification, karnofsky performance 
score, histology, and margin to the planning target volume. 
Only the last four showed significant association in the 
multivariate analyses. 
Conclusions: stereotactic radiosurgery is a safe and may be 
an effective treatment option for selected patients diagnosed 
with recurrent high-grade glioma. The identified prognostic 
factors could help to individualise the treatment.  
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Purpose/Objective: Kaposi’s sarcoma (KS) is a low grade 
malignant vascular endothelial tumor which has a viral 
etiology; KS herpes virus (KSHV). It was found to be endemic 
in the Central and Southern Africa. Sporadic cases are found 
in the Mediterranean region. With the advent of HIV- AIDS 
epidemic, the incidence of Kaposi's sarcoma has increased. 
The Aim of the study is to determine the demographics of the 
disease, treatment and their outcomes. 
Materials and Methods: The study is a retrospective study of 
patients with Kaposi's sarcoma who presented to the unit 
from 2004-2013. It evaluated all histologically confirmed 
cases of KS for demographic information, HIV status, degree 
S722                                                                                                                                         3rd ESTRO Forum 2015 
 
of immunosuppression (WHO criteria), use of antiretroviral 
therapy, CD4 counts, location of lesions, treatment used 
(surgery, chemotherapy, radiotherapy, combination), 
treatment duration, and estimates on survival. SPSS version 
20 was used in the statistical analysis. 
Results: A total of 63 cases fit the study criteria out of 113 
seen. Ratio of Epidemic vs. Endemic KS was 1: 1.8. Male to 
female ratio was 2.5: 1.The median age at presentation was 
48yrs (range 18-80yrs). The most frequent site was skin (90%) 
with 84% on the lower extremity and 6% disseminated. About 
60% of the HIV positive patients were on HAART. Median CD4 
count was 250cells/mm3 (range 1-549). Twenty four percent 
of the patients had both chemotherapy and radiotherapy, 
16% had chemotherapy only, 22% had radiotherapy only and 
38% refused treatment. The commonest chemotherapeutic 
agent used was Vincristine and others were Paclitaxel, 
Doxorubicin and Bleomycin. In all, 72% of the patients who 
received radiotherapy had good control with a minimum BED 
of 17.6Gy, out of which 52% had BED of 20Gy or less, 43% had 
BED between 20Gy and 40Gy and 5% greater than 40Gy. The 
most frequently prescribed radiation dose was 8Gy as a single 
dose. Other dose prescriptions used were 20Gy in 5 fractions 
and 30Gy in 10 fractions. The median follow period was 85 
days (range 1- 2241days). The overall survivals at 5years and 
10years were 41% and 6% respectively. 
Conclusions: The pattern of Kaposi’s sarcoma in Ghana 
differs from that of other Sub-Saharan African countries due 
to a relatively low rate of HIV infections, with endemic 
Kaposi sarcoma being almost twice as common. Radiotherapy 
is associated with good and durable local control to 
symptomatic sites. A BED at least 17.6Gy is required for local 
control of the disease. Follow up was however a limitation to 
this study. 
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Purpose/Objective: Breast sarcoma is a rare malignancy 
accounting for less than 1 percent of all breast malignancies 
and <5% of all soft tissue sarcomas It is a histologically 
heterogeneous non-epithelial malignancy arising from the 
breast connective tissue. Breast sarcoma can develop de novo 
or following radiation therapy. We present a case series 
analysis of all breast cancer sarcomas presented to our 
institution in a 14 year period. 
Materials and Methods: Data was retrospectively collected 
on all patients presenting with a histological diagnosis of 
breast sarcoma between 1999 and 2012. All cases have had 
histological confirmation of sarcoma diagnosis. Information 
collected on: age at diagnosis, presentation, tumour size, 
pathological and radiographic findings, treatment, breast 
cancer mortality and past medical history including prior 
radiotherapy. 
Results: Twenty-two patients were identified aged between 
15 and 84 (mean 54 years). Ten cases were in the right breast 
and ten within the left breast, one case was bilateral. 
Sixteen cases presented as a primary breast sarcoma, five 
presented as metastasis to the breast and skin overlying the 
breast, one presented as a metastasis from the breast. 
Tumour size was available for seventeen specimens ranging 
between 6mm and 130mm (mean 44.47mm). 
Histopathological diagnosis included sarcoma (not further 
specified) n=2, rhabdomyosarcoma n=3, myofibroblastic 
sarcoma n=2, leimyosarcoma n=1, angiosarcoma n=5, 
desmoids tumour with fibromatosis n=1, osteosarcoma n=1, 
liposarcoma n=1, spindle cell sarcomatosis n=1, stromal 
sarcoma n=2. 3 specimens revealed sarcomatoid features of 
uncertain origin. Surgical management included mastectomy 
(n=7), wide local excision (n=9), lumpectomy (n=3), one 
patient declined operative management and three patients 
lacked full clinical details.Ten patients presented with 
sarcoma in a previous radiotherapy field of which five of 
these were histologically angiosarcoma. Local recurrence was 
observed in two patients, two patients had distant metastatic 
disease. five patients presented with metastatic disease to 
the breast or the overlying skin, sixteen tumours presented 
primarily in the breast and one presented as metastasis to 
the tonsil.Ten of the twenty two patients died with a 
diagnosis of breast cancer. Tumour size > 5cm was not 
significantly associated with 5 year overall survival(p=0.63) in 
17 specimens for which tumour size was available. Influence 
of tumour grade on overall survival was not assessed due to 
insufficient clinical details. 
Conclusions: Our results indicate that prognosis in patients 
with breast sarcoma is still poor. Larger cohort of patients 
and more clinical research is required to improve treatment 
outcomes in patients with breast sarcomas. 
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Purpose/Objective: To assess the feasibility and local control 
of adjuvant radiotherapy in patients with BM after surgery. 
To analyze prognostic factors. 
Materials and Methods: 49 patients with resected BM from 
the lung, breast, gastrointestinal, genitourinary, and 
unknown origin were recruited (43 patients with 1 lesion and 
6 patients with 2 lesions). Ten patients were RPA class I, 38 
patients class II, and 1 patient class III. The GPA score was 
0.5 in 1 patient, 1.5 in 15 patients, 2.0 in 8 patients, 2.5 in 5 
patients, 3.0 in 12 patients, 3.5 in 6 patients, and 4.0 in 2 
patients. 24 out of 49 patients had synchronous BM. 
Results: A total of 11 patients received a single treatment 
session, 27 patients received hypofractionated stereotactic 
radiation regimen, while 11 cases were treated with focal 3D 
radiation with/without cone beam. After a median follow-up 
of 15.2 months, the median disease-free progression time 
was 11.3 months (95% CI, 6.4-16.3). The actuarial local 
